Extension Study to Investigate the Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate (BIA 2-093) in the Recurrence Prevention of Bipolar I Disorder [EXTENSION OF 700231317]

Trial Profile

Extension Study to Investigate the Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate (BIA 2-093) in the Recurrence Prevention of Bipolar I Disorder [EXTENSION OF 700231317]

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2015

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Bipolar I disorders
  • Focus Therapeutic Use
  • Sponsors Bial
  • Most Recent Events

    • 15 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top